Cutting the cost of South African antiretroviral therapy using newer, safer drugs

Cutting the cost of South African antiretroviral therapy using newer, safer drugs

Antiretrovirals are a significant cost driver for HIV programmes. Current first-line regimens have performed well in real-life programmes, but have a low barrier to virological resistance and still carry toxicity that limits adherence. New drug developments may mean that we have access to safer, mor...

Full description

Bibliographic Details
Main Authors: W F Venter, B Kaiser, Y Pillay, F Conradie, G B Gomez, P Clayden, M Matsolo, C Amole, L Rutter, F Abdullah, E J Abrams, C P Casas, M Barnhart, A Pillay, A Pozniak, A Hill, L Fairlie, M Boffito, M Moorhouse, M Chersich, C Serenata, J Quevedo, G Loots
Format: Article
Language:English
Published: Health and Medical Publishing Group 2017-01-01
Series:South African Medical Journal
Subjects:
Antiretroviral therapy
costs
safer drugs
Online Access:http://www.samj.org.za/index.php/samj/article/view/11770/7918

Internet

http://www.samj.org.za/index.php/samj/article/view/11770/7918

Similar Items